Clinical Trial Update: Afatinib Plus Nimotuzumb for NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 1/2 study evaluating the combination of afatinib and nimotuzumab for non-small cell lung cancer, with current status listed as …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: NSCLC | Phase 1, Phase 2 | Status: UNKNOWN